Treatment of uremic hyperphosphatemia--is there still a need for aluminum salts?
Aluminum-containing phosphate binders have been widely employed in the past in the management of uremic hyperphosphatemia. However, an increasing number of reports on aluminum toxicity has stimulated efforts to replace this therapy by safer methods. The aim of the present review is to critically evaluate other treatment strategies. It appears that aluminum-containing phosphate binders should no longer be considered the treatment of choice for controlling uremic hyperphosphatemia. Calcium carbonate, calcium citrate, magnesium carbonate and a mixture of ketoanalogues and amino acids present important therapeutical alternatives which could replace aluminum-containing phosphate binders in the majority of patients. However, it is mandatory, as these therapies also carry some risks, that side effects are detected early.
Schaefer
K
K
St. Joseph-Krankenhaus I, Medizinische Abteilung II, Berlin.
von Herrath
D
D
Erley
C M
CM
D000534:Alum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000535:Aluminum / Q000627:therapeutic use*; D006801:Humans; D010710:Phosphates / Q000097:blood*; D014511:Uremia / Q000188:drug therapy*
D000534:Alum Compounds; D010710:Phosphates; D000535:Aluminum